Takeda Announces New Assignments of Directors
Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An external director will continue to chair the Board of Directors.
Takeda highly values strong, independent governance and its Board of Directors helps to ensure that all decisions and actions are in the best interests of global stakeholders and aligned with the company’s values. This robust corporate governance model has been, and will continue to be, critical to Takeda's success.
Details of the new assignments are as follows:
1. New Assignment of Directors Who Are Not Audit and Supervisory Committee Members (Effective
|
Category |
Role |
|
|
Internal |
Existing |
Representative Director, President & Chief Executive Officer |
|
Internal |
New |
Director, Chief Financial Officer |
|
Internal |
Existing |
Director, President, Research & Development |
|
External |
Existing |
External Director, Chair of the Board Meeting |
|
External |
Existing |
External Director |
|
External |
Existing |
External Director |
|
External |
New |
External Director |
|
External |
Existing |
External Director |
|
External |
Existing |
External Director |
|
External |
Existing |
External Director |
2. Directors Who Are Audit and Supervisory Committee Members (Effective
|
Category |
Role |
|
Koji Hatsukawa |
External |
Existing |
External Director, Head of |
|
External |
New |
|
|
External |
Existing |
|
|
External |
Existing |
|
3. New Assignment of
Nomination committee:
(Observer:
Compensation committee:
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619545549/en/
Media Contacts:
Japanese Media
shoko.honda@takeda.com
+81 (0) 70-2687-3620
brendan.jennings@takeda.com
+81 (0) 80-2705-8259
Source: